{"id":"W4281874725","doi":"10.1200/jco.2022.40.16_suppl.tps8071","title":"TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pfizer (Canada); Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; CD47; Multiple myeloma; In vivo; Neutropenia; Pharmacodynamics; Pharmacology; Blockade; Bone marrow; Bortezomib; Phagocytosis; Cancer research; Oncology; Internal medicine; Immunology; Pharmacokinetics; Receptor; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001158574,0.001834038,0.001322728,0.0006336841,0.0004901084,0.001249644,0.0008919894,0.001515428,0.005927202],"category_scores_gemma":[0.0005266058,0.0005811512,0.001026478,0.0005376629,0.0006887577,0.0008030682,0.0004967478,0.003601403,0.001486568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001134055,"about_ca_system_score_gemma":0.001407924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001003644,"about_ca_topic_score_gemma":0.003579418,"domain_scores_codex":[0.9997134,0.00008718688,0.00001184239,0.00005818221,0.00004424648,0.00008524],"domain_scores_gemma":[0.9995514,0.00003027494,0.00008395363,0.00002602276,0.00002845386,0.0002798591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.329264,0.109525,0.009774238,0.001894156,0.001883178,0.0008614411,0.0006325923,0.006655643,0.1533913,0.001467312,0.03871003,0.3459413],"study_design_scores_gemma":[0.5512788,0.3956921,0.02120211,0.00012736,0.0005932414,0.00122531,0.0001004204,0.00280916,0.007659951,0.0008542196,0.01837533,0.00008197884],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765496,0.00565222,0.001218004,0.002196642,0.0003088837,0.004187562,0.003120579,0.0005047943,0.006261714],"genre_scores_gemma":[0.9636439,0.004033359,0.003318229,0.004269576,0.0003521754,0.005503227,0.008249737,0.0001391862,0.01049049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005927202,"threshold_uncertainty_score":0.0198285,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1331947736445989,"score_gpt":0.4655549709589065,"score_spread":0.3323601973143075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}